
Cantargia Q4 2022 - Progress in Triple-Negative Breast Cancer

In the fourth quarter, Cantargia continued with its ongoing programs and strategy. The share price reached a historical low but has begun to recuperate since early January 2023. In February, after the end of Q4, solid efficacy results were presented from the phase I part of TRIFOUR in triple-negative breast cancer.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Cantargia Q4 2022 - Progress in Triple-Negative Breast Cancer